Fluoroalkane modified cationic polymers for personalized mRNA cancer vaccines

Li, Junyan; Wu, Yuanyuan; Xiang, Jian; Wang, Hairong; Zhuang, Qi; Wei, Ting; Cao, Zhiqin; Gu, Qingyang; Liu, Zhuang; Peng, Rui

doi:10.1016/j.cej.2022.140930

Cited by 31 publications

(25 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, Li and colleagues synthesized fluoroalkane modified PEI (F-PEI) to facilitate the intracellular delivery of tumor antigen-encoding mRNA. 160 Their vaccine was capable of inducing antigen-specific CD8+ T cell immune responses without the use of additional adjuvants. To evaluate antitumor efficacy, mice were inoculated with OVA-expressing B16 melanoma cells and were treated twice with OVA mRNA encapsulated in F-PEI.…”

Section: Nonviral Mrna Therapeutic Melanoma Vaccinesmentioning

confidence: 99%

“…Besides LNPs, preclinical studies have shown polymer-based carriers can be used to deliver mRNA melanoma vaccines. Recently, Li and colleagues synthesized fluoroalkane modified PEI (F-PEI) to facilitate the intracellular delivery of tumor antigen-encoding mRNA . Their vaccine was capable of inducing antigen-specific CD8+ T cell immune responses without the use of additional adjuvants.…”

Section: Nonviral Mrna Therapeutic Melanoma Vaccinesmentioning

confidence: 99%

“…(a) Graphical overview of F-PEI mRNA vaccine preparation (top) and tumor volumes and survival curves of mice bearing B16-OVA tumors in different treatment groups (bottom). Reproduced with permission from ref . Copyright 2023 Elsevier.…”

Section: Nonviral Mrna Therapeutic Melanoma Vaccinesmentioning

confidence: 99%

See 2 more Smart Citations

Advances in Nonviral mRNA Delivery Materials and Their Application as Vaccines for Melanoma Therapy

Neill,

Romero,

Fenton

2023

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

Messenger RNA (mRNA) vaccines are promising platforms for cancer immunotherapy because of their potential to encode for a variety of tumor antigens, high tolerability, and capacity to induce strong antitumor immune responses. However, the clinical translation of mRNA cancer vaccines can be hindered by the inefficient delivery of mRNA in vivo. In this review, we provide an overview of mRNA cancer vaccines by discussing their utility in treating melanoma. Specifically, we begin our review by describing the barriers that can impede mRNA delivery to target cells. We then review native mRNA structure and discuss various modification methods shown to enhance mRNA stability and transfection. Next, we outline the advantages and challenges of three nonviral carrier platforms (lipid nanoparticles, polymeric nanoparticles, and lipopolyplexes) frequently used for mRNA delivery. Last, we summarize preclinical and clinical studies that have investigated nonviral mRNA vaccines for the treatment of melanoma. In writing this review, we aim to highlight innovative nonviral strategies designed to address mRNA delivery challenges while emphasizing the exciting potential of mRNA vaccines as next-generation therapies for the treatment of cancers.

show abstract

Section: Nonviral Mrna Therapeutic Melanoma Vaccinesmentioning

confidence: 99%

Section: Nonviral Mrna Therapeutic Melanoma Vaccinesmentioning

confidence: 99%

See 1 more Smart Citation

Advances in Nonviral mRNA Delivery Materials and Their Application as Vaccines for Melanoma Therapy

Neill,

Romero,

Fenton

2023

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

show abstract

“…This CP platform promoted mRNA molecules to cross the plasma membrane and escape from the endosome, ensuring high transfection efficiency. In another example, they grafted fluoroalkanes to PEI (F-PEI) for delivering the model antigen OVA (Figure A) . Such F-PEI/mRNA cancer vaccines promoted the intracellular delivery of mRNA and significantly delayed tumor growth in established B16-OVA melanoma mouse models (Figure B).…”

Section: Construction Of Mrna Cancer Vaccinementioning

confidence: 99%

Section: Construction Of Mrna Cancer Vaccinementioning

confidence: 99%

mRNA Cancer Vaccines: Construction and Boosting Strategies

Liu,

Huang,

Yang

et al. 2023

ACS Nano

View full text Add to dashboard Cite

In late 2020, the U.S. Food and Drug Administration (FDA) approved a lipid-based mRNA vaccine for the prevention of COVID-19, which has pushed this field to be more closely studied and motivated researchers to delve deeper into mRNA therapeutics. To date, the research on mRNA cancer vaccines has been developed rapidly, and substantial hopeful therapeutic results have been achieved against various solid tumors in clinical trials. In this review, we first introduce three main components of mRNA cancer vaccines, including mRNA antigens, adjuvants, and delivery vectors. Engineering these components can optimize the therapeutic effects of mRNA cancer vaccines. For instance, appropriate modification of mRNA structure can alleviate the poor stability and innate immunogenicity of mRNA, and the use of mRNA delivery vectors can address the issues of low delivery efficiency in vivo. Second, we emphatically discuss some strategies to further improve the efficacy of mRNA cancer vaccines, namely modulating the immunosuppressive tumor environment, optimizing administration routes, achieving targeting delivery to intended tissues or organs, and employing combination therapy. These strategies can strengthen the tumor inhibitory ability of mRNA cancer vaccines and increase the possibility of tumor elimination. Finally, we point out some challenges in the clinical practice of mRNA cancer vaccines and offer our perspectives on future developments in this rapidly evolving field. It is anticipated that mRNA cancer vaccines will be rapidly developed for clinical cancer therapy in the near future.

show abstract

Cellular Trafficking of Nanotechnology‐Mediated mRNA Delivery

Huang,

Deng,

Wang

et al. 2023

Advanced Materials

View full text Add to dashboard Cite

Messenger RNA (mRNA)‐based therapy has emerged as a powerful, safe, and rapidly scalable therapeutic approach that involves technologies for both mRNA itself and the delivery vehicle. Although there are some unique challenges for different applications of mRNA therapy, a common challenge for all mRNA therapeutics is the transport of mRNA into the target cell cytoplasm for sufficient protein expression. This review is focused on the behaviors at the cellular level of nanotechnology‐mediated mRNA delivery systems, which have not been comprehensively reviewed yet. First, the four main therapeutic applications of mRNA are introduced, including immunotherapy, protein replacement therapy, genome editing, and cellular reprogramming. Second, common types of mRNA cargos and mRNA delivery systems are summarized. Third, strategies to enhance mRNA delivery efficiency during the cellular trafficking process are highlighted, including accumulation to the cell, internalization into the cell, endosomal escape, release of mRNA from the nanocarrier, and translation of mRNA into protein. Finally, the challenges and opportunities for the development of nanotechnology‐mediated mRNA delivery systems are presented. This review can provide new insights into the future fabrication of mRNA nanocarriers with desirable cellular trafficking performance.

show abstract

Fluoroalkane modified cationic polymers for personalized mRNA cancer vaccines

Cited by 31 publications

References 43 publications

Advances in Nonviral mRNA Delivery Materials and Their Application as Vaccines for Melanoma Therapy

Advances in Nonviral mRNA Delivery Materials and Their Application as Vaccines for Melanoma Therapy

mRNA Cancer Vaccines: Construction and Boosting Strategies

Cellular Trafficking of Nanotechnology‐Mediated mRNA Delivery

Contact Info

Product

Resources

About